Biopharma financing during the first quarter of 2024 totaled $30.1bn from 298 deals. The follow-on public offering (FOPO) category made up the greatest proportion (36%) of the aggregate Q1 financing dollars (see Exhibit 1). During Q1, there were 81 FOPOs in all, of which 36 deals totaled $100m or more.
Financing Quarterly Statistics, Q1 2024
A Look At Financing Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, January-March 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
More from Deal-Making
More from In Vivo
• By
AI-related deal activitiy in the first quarter of 2025 was punctuated by a last-minute $600m raise for Isomorphic Labs.
• By
The process of manufacturing medicines can often be complex, expensive and harmful to the environment. Initiatives like RESILIENCE UK are seeking to simplify this process, utilizing VR technology to create a more sustainable learning environment for both students and companies.
• By
Lundbeck CEO Charl van Zyl spoke with In Vivo about the Danish company’s multipronged transformation, one that involves a rethink of company culture, pipeline strategy and a sharpened focus on innovation in rare neurological disorders.